Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d‘Etudes des Lymphomes de l‘Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Wang L, Li L-R, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):1–23.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Fairbrother WJ, Leverson JD, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–284.
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–656.
   PubMed Web of Science ®Google Scholar
• Green DR. A BH3 mimetic for killing cancer cells. Cell. 2016;165(7):1560.
   PubMed Web of Science ®Google Scholar
• Liu Y, Mondello P, Erazo T, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci USA. 2018;115(47):12034–12039.
   PubMed Web of Science ®Google Scholar
• D’Aguanno S, Del Bufalo D. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer. Cells. 2020;9(5):1287.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90(1):244–251.
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489–500.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–609.
   PubMed Web of Science ®Google Scholar
• Boiko S, Proia TA, San Martin M, et al. Targeting bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas. Blood. 2021;137(21):2947–2957.
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304–3313.
   PubMed Web of Science ®Google Scholar
• Esteve-Arenys A, Valero J, Chamorro-Jorganes A, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830–1844.
   PubMed Web of Science ®Google Scholar
• Brien G, Trescol-Biemont M-C, Bonnefoy-Bérard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene. 2007;26(39):5828–5832.
   PubMed Web of Science ®Google Scholar
• Huhn AJ, Guerra RM, Harvey EP, et al. Selective covalent targeting of anti-apoptotic BFL-1 by cysteine-reactive stapled peptide inhibitors. Cell Chem Biol. 2016;23(9):1123–1134.
   PubMed Web of Science ®Google Scholar
• Harvey EP, Hauseman ZJ, Cohen DT, et al. Identification of a covalent molecular inhibitor of anti-apoptotic BFL-1 by disulfide tethering. Cell Chem Biol. 2020;27(6):647–656.e6.
   PubMed Web of Science ®Google Scholar
• Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19(1):67–74.
   PubMed Web of Science ®Google Scholar
• Simpson LA, Burwell EA, Thompson KA, et al. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood. 2006;107(12):4695–4702.
   PubMed Web of Science ®Google Scholar
• Ottina E, Tischner D, Herold MJ, et al. A1/Bfl-1 in leukocyte development and cell death. Exp Cell Res. 2012;318(11):1291–1303.
   PubMed Web of Science ®Google Scholar
• Barile E, Marconi GD, De SK, et al. hBfl-1/hNOXA interaction studies provide new insights on the role of Bfl-1 in cancer cell resistance and for the design of novel anticancer agents. ACS Chem Biol. 2017;12(2):444–455.
   PubMed Web of Science ®Google Scholar
• Chen I-C, Sethy B, Liou J-P. Recent update of HDAC inhibitors in lymphoma. Front Cell Dev Biol. 2020;8:576391.
   PubMed Web of Science ®Google Scholar
• Crump M, Coiffier B, Jacobsen E, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964–969.
   PubMed Web of Science ®Google Scholar
• Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–194.
   PubMed Web of Science ®Google Scholar
• Makki MS, Heinzel T, Englert C. TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res. 2008;36(12):4067–4078.
   PubMed Web of Science ®Google Scholar
• Merck, pre-designed shRNA; 2020. https://www.sigmaaldrich.com/KR/ko/semi-configurators/shrna?activeLink=selectClones [cited 2020 Oct 10].
   Google Scholar
• Jung H, Kim MJ, Kim DO, et al. TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress. Cell Metab. 2013;18(1):75–85.
   PubMed Web of Science ®Google Scholar
• Suh H-W, Yun S, Song H, et al. TXNIP interacts with hEcd to increase p53 stability and activity. Biochem Biophys Res Commun. 2013;438(2):264–269.
   PubMed Web of Science ®Google Scholar
• Marks P, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107(4):600–608.
   PubMed Web of Science ®Google Scholar
• Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020;20(1):1–14.
   PubMed Web of Science ®Google Scholar
• Esteve-Arenys A, Roue G. BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma. Oncoscience. 2018;5(3–4):59–61.
   PubMedGoogle Scholar
• Prukova D, Andera L, Nahacka Z, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25(14):4455–4465.
   PubMed Web of Science ®Google Scholar
• Wang H, Guo M, Wei H, et al. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):1–18.
   PubMed Web of Science ®Google Scholar
• Morales AA, Olsson A, Celsing F, et al. High expression of Bfl‐1 contributes to the apoptosis resistant phenotype in B‐cell chronic lymphocytic leukemia. Int J Cancer. 2005;113(5):730–737.
   PubMed Web of Science ®Google Scholar
• Wright GW, Phelan JD, Coulibaly ZA, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14.
   PubMed Web of Science ®Google Scholar
• Lee C, Song H, Song S, et al. Not BCL2 but BFL1 is overexpressed and have strong correlation with NFkB pathway in diffuse large B-cell lymphoma. Atlanta, Georgia:AACR; 2019.
   Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826–838.
   PubMed Web of Science ®Google Scholar